PNT Stock Overview
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
POINT Biopharma Global Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.50 |
| 52 Week High | US$14.35 |
| 52 Week Low | US$6.57 |
| Beta | -0.0026 |
| 1 Month Change | -9.49% |
| 3 Month Change | 87.41% |
| 1 Year Change | 75.07% |
| 3 Year Change | -10.20% |
| 5 Year Change | n/a |
| Change since IPO | 3.99% |
Recent News & Updates
Recent updates
POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates
Aug 20
We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth
Feb 01A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)
Oct 18Point Biopharma plummets on announcing common stock offering
Sep 13POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05
Aug 12Shareholder Returns
| PNT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 1.0% | 1.2% |
| 1Y | 75.1% | 0.7% | 24.9% |
Return vs Industry: PNT exceeded the US Biotechs industry which returned 6% over the past year.
Return vs Market: PNT exceeded the US Market which returned 24.8% over the past year.
Price Volatility
| PNT volatility | |
|---|---|
| PNT Average Weekly Movement | 24.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PNT's share price has been volatile over the past 3 months.
Volatility Over Time: PNT's weekly volatility has increased from 13% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 129 | Joe McCann | www.pointbiopharma.com |
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies.
POINT Biopharma Global Inc. Fundamentals Summary
| PNT fundamental statistics | |
|---|---|
| Market cap | US$1.33b |
| Earnings (TTM) | US$96.55m |
| Revenue (TTM) | US$243.69m |
13.8x
P/E Ratio5.5x
P/S RatioIs PNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNT income statement (TTM) | |
|---|---|
| Revenue | US$243.69m |
| Cost of Revenue | US$0 |
| Gross Profit | US$243.69m |
| Other Expenses | US$147.14m |
| Earnings | US$96.55m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 100.00% |
| Net Profit Margin | 39.62% |
| Debt/Equity Ratio | 0% |
How did PNT perform over the long term?
See historical performance and comparison